HitGen Licenses Cancer Drug Candidates to Cancer Research UK

HitGen Ltd. of Chengdu and Houston signed a license agreement with Cancer Research UK and its commercial arm, Cancer Research Technology (CRT), to develop a novel class of drugs against lung cancer. A drug discovery biotech, HitGen provided several novel molecules for a target identified by Cancer Research. Cancer Research UK’s Drug Discovery Unit at The University of Manchester will be responsible for early development. HitGen will be eligible for milestone payments, though further financial details of the agreement were not disclosed. More details.... Share this with colleagues: // //